Catheter Precision (VTAK) is like:

• Siemens Healthineers or Philips Healthcare for advanced 3D cardiac mapping, helping doctors pinpoint the exact source of irregular heartbeats.
• Intuitive Surgical (maker of the da Vinci surgical robot) but specializing in robotic control and precision for catheter-based heart procedures.
• A hyper-focused version of Boston Scientific's or Abbott Laboratories' electrophysiology divisions, developing specialized devices and imaging for heart rhythm disorders.

• View into Ventricular Onset System (VIVO System): A non-invasive imaging system providing 3D cardiac mapping to localize sites of origin for idiopathic ventricular arrhythmias before EP procedures.
• LockeT: A suture retention device.
• Amigo Remote Catheter System: A robotic arm used as a catheter control device.

Catheter Precision (VTAK) primarily sells its electrophysiology products and medical devices to organizations and institutions within the healthcare sector. Based on the company's description, its major customers are:

• Hospitals: These institutions are the primary purchasers of advanced medical systems such as the View into Ventricular Onset System, LockeT suture retention devices, and the Amigo Remote Catheter System, which are utilized in electrophysiology procedures.
• Electrophysiology Laboratories/Cardiology Clinics: Specialized departments within hospitals or independent clinics focused on cardiac care and arrhythmia treatment are key customers for Catheter Precision's dedicated products.
• Physician Groups: Groups of cardiologists and electrophysiologists may also procure these technologies for use within their collective practices or associated facilities.

As the company's background description does not name specific customer companies, no public company symbols can be provided for these customer categories.

David Jenkins, Chief Executive Officer & Executive Chairman

David Jenkins has over thirty years of experience in the medical device field, primarily with small companies. He previously operated two other cardiac electrophysiology companies as CEO and Chairman: Arrhythmia Research Technology, Inc., and EP MedSystems, Inc.. He also founded Transneuronix, Inc., a company focused on implantable neurostimulators for obesity and weight loss. EP MedSystems, Inc. was acquired by St Jude Medical (now owned by Abbott) in 2008, and Transneuronix was acquired by Medtronic in 2005 for $260 million. Mr. Jenkins began his career as a CPA with Coopers and Lybrand. He also founded Catheter Robotics in 2007, which later expanded its product offerings to become Catheter Precision. He has personally invested over $30 million into the company's predecessor.

Philip Anderson, Chief Financial Officer

Philip Anderson was appointed as Chief Financial Officer of Catheter Precision in January 2025. His background encompasses executive management across various industries, experience managing hedge funds at the partner level, and a prior role in investment banking. He has previously served as CFO for other companies, including Heritage Distilling Corporation, Crown Electrokinetics Corp., and Kubient, Inc., a provider of digital advertising market fraud prevention solutions.

Missiaen Huck, Chief Operating Officer

Missiaen Huck serves as the Chief Operating Officer of Catheter Precision, Inc..

Margrit Thomassen CPA, Controller & Secretary

Margrit Thomassen holds the position of Controller & Secretary for Catheter Precision, Inc.. She previously served as the Interim Chief Financial Officer for the company.

The key risks to Catheter Precision (VTAK) primarily revolve around its severe financial distress, the inherent challenges of market acceptance and regulatory hurdles in the medical device industry, and significant stock volatility impacting shareholders.

1. Significant Financial Distress and Going Concern Doubt
   Catheter Precision faces substantial financial challenges, as evidenced by a Piotroski F-Score of 3, indicating poor business operations, and a concerning three-year revenue growth decline of -51.9%. The company exhibits significant operational inefficiencies with an operating margin of -1693.97% and a net margin of -2393.84%. Its balance sheet reveals liquidity constraints, with a current ratio of 0.46, and an Altman Z-Score of -18.73, placing it in the distress zone and signaling a potential risk of bankruptcy within two years. Furthermore, the company announced in April 2025 that its audit opinion contained "substantial doubt about its ability to continue as a going concern." This ongoing liquidity strain and history of material operating losses pose an existential threat to the business.
2. Regulatory Challenges and Market Acceptance of Products
   As a medical device company, Catheter Precision is subject to extensive and continuous regulation by the FDA and other regulatory agencies. This includes the risk of product recalls, revocations, or suspensions, even after regulatory approvals, which could divert resources and harm the company's reputation. Despite its lead product, VIVO, having received FDA clearance and a CE Mark for European commercialization, and LockeT being an FDA-registered Class 1 device, the company's ability to generate significant revenue is contingent on the acceptance of its products by hospitals, physicians, and patients. The company operates within a competitive medical devices market, and its low reported revenue of $0.73 million highlights ongoing challenges in achieving broad market adoption and sales growth for its specialized products.
3. High Stock Volatility and Shareholder Dilution
   Catheter Precision's stock has experienced significant price fluctuations and high volatility over recent periods. This volatility, characterized by a Standard Deviation of 8.21 and a 7.8062% risk over a 90-day horizon, suggests considerable uncertainty for investors. Adding to this risk, shareholders have experienced substantial dilution in the past year, which could make future capital raises challenging without further impacting existing shareholders. This high volatility, often a symptom of underlying financial instability, contributes to a challenging environment for attracting and retaining investors.

Catheter Precision (VTAK) develops and delivers electrophysiology products aimed at improving the lives of patients with cardiac arrhythmias. The addressable markets for their main products are as follows:

View into Ventricular Onset System (VIVO)

Catheter Precision's VIVO system is a non-invasive imaging system that provides 3D cardiac mapping to localize the sites of origin of idiopathic ventricular arrhythmias prior to EP procedures. While the company believes VIVO addresses a "critically underserved market," a specific addressable market size in USD for the VIVO system has not been identified in the available information.

LockeT

LockeT is a suture retention device designed to assist in wound closure after percutaneous venous punctures. This product falls within the broader categories of suture anchor devices, catheter fixation devices, and wound closure devices.

• The global suture anchor devices market was valued at USD 815.6 million in 2024 and is projected to reach USD 1,003.4 million by 2030. North America held the largest revenue share of 41.0% in this market in 2024. Another estimate projects the global suture anchor devices market to be valued at USD 797.4 million in 2025, reaching USD 1,262.2 million by 2035.
• The global catheter fixation device market size was valued at USD 1.45 billion in 2023 and is projected to reach USD 2.68 billion by 2032. North America holds the largest share of this market.
• The global wound closure devices market is expected to increase from USD 15,831.38 million in 2024 to USD 28,128.89 million by 2032, with North America expected to dominate the market.

Amigo Remote Catheter System

The Amigo Remote Catheter System is a robotic arm that serves as a catheter control device.

• The global robotic catheterization systems market was valued at USD 61.6 million in 2026 and is projected to reach USD 214.8 million by 2036, growing at a Compound Annual Growth Rate (CAGR) of 13.30%. Another source estimates the Robotic Catheterization Systems Market was valued at USD 92.16 million in 2025 and is expected to increase to USD 242.17 million by 2032, growing at a CAGR of 14.8%.
• The global robotic vascular catheter system market was valued at USD 250 million in 2024 and is expected to increase to USD 570 million by 2031, with a CAGR of 12.6%. This market data covers 65 countries across North America, Latin America, Western Europe, Central & Eastern Europe, Middle East, Asia-Pacific, and Africa.

Catheter Precision (VTAK) is anticipated to drive future revenue growth over the next 2-3 years through a combination of its core medical device advancements and a significant strategic expansion into the regional aviation market.

Here are 3-5 expected drivers of future revenue growth:

1. Expansion and Scaling of the Flyte Regional Aviation Platform: A primary driver of future revenue growth is expected to come from the recently acquired Flyte aviation platform. Catheter Precision has secured up to $88 million in institutional financing specifically to fund Flyte's fleet expansion, acquire more aircraft, and broaden its market presence across additional regional corridors. Management believes this strategy positions Catheter Precision for rapid fleet growth and expansion into high-demand regional markets.
2. Increased Adoption and International Expansion of VIVO and LockeT Products: In its traditional medical device segment, Catheter Precision expects continued revenue growth from the increasing sales and international expansion of its VIVO and LockeT products. The company reported significant year-over-year revenue growth for its medical devices in Q3 2025, with LockeT and VIVO sales gaining traction in international markets following regulatory approvals, such as the CE Mark for LockeT.
3. Strategic Capital Allocation and Balance Sheet Improvements: The substantial institutional financing commitments of up to $88 million secured in March 2026 are crucial for funding the company's growth initiatives. This capital is intended to support not only the Flyte platform's expansion but also to provide funding for Catheter Precision's medical device operations, while simultaneously aiming to simplify the balance sheet and reduce legacy liabilities, thereby enabling accelerated growth across both segments.
4. Continuous Product Innovation in Electrophysiology: Catheter Precision's commitment to developing and bringing new solutions to market in the cardiac electrophysiology space remains a foundational driver. The company's focus on continuous product innovation and collaboration with physicians to advance its electrophysiology products, such as the VIVO system, is expected to enhance its offerings and market penetration for treating cardiac arrhythmias.

Share Issuance

• Catheter Precision registered shares issuable under two employee equity programs in June 2025: the 2023 Equity Incentive Plan and a stock-option grant to its CFO.
• A 1-for-19 reverse stock split was implemented on August 15, 2025, to assist the company in maintaining its listing on the NYSE American.
• The number of outstanding shares for VTAK increased by 1,292.59% over a one-year period as of a recent reporting date (likely within the last 12 months from March 2026).

Inbound Investments

• Catheter Precision secured up to $36.5 million in strategic institutional financing in February 2026 to support accelerated growth.
• The company received institutional financing commitments of up to $88 million in March 2026, intended to fund the expansion of its Flyte fleet, market entry, platform scaling, and balance sheet simplification.
• A $1.5 million private placement was announced in May 2025.

Outbound Investments

• Catheter Precision acquired a 19.98% strategic stake in Fly Flyte, Inc., an AI-enabled aviation company, in February 2026.
• A definitive merger agreement to acquire 100% of Fly Flyte Inc. was announced by the company in March 2026.
• Catheter Precision divested its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer in February 2026, receiving an upfront cash payment, a 5% equity stake in the acquiring company, and a royalty agreement.

Capital Expenditures

• Capital expenditures for Catheter Precision were $0 in the third quarter of 2025, representing a 100% decrease from the prior quarter.
• In the last 12 months, capital expenditures were reported as -$17,000.